It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The composition of the gastrointestinal microbiota influences systemic immune responses, but how this affects infectious disease pathogenesis and antibiotic therapy outcome is poorly understood. This question is rarely examined in humans due to the difficulty in dissociating the immunologic effects of antibiotic-induced pathogen clearance and microbiome alteration. Here, we analyze data from two longitudinal studies of tuberculosis (TB) therapy (35 and 20 individuals) and a cross sectional study from 55 healthy controls, in which we collected fecal samples (for microbiome analysis), sputum (for determination of Mycobacterium tuberculosis (Mtb) bacterial load), and peripheral blood (for transcriptomic analysis). We decouple microbiome effects from pathogen sterilization by comparing standard TB therapy with an experimental TB treatment that did not reduce Mtb bacterial load. Random forest regression to the microbiome-transcriptome-sputum data from the two longitudinal datasets reveals that renormalization of the TB inflammatory state is associated with Mtb pathogen clearance, increased abundance of Clusters IV and XIVa Clostridia, and decreased abundance of Bacilli and Proteobacteria. We find similar associations when applying machine learning to peripheral gene expression and microbiota profiling in the independent cohort of healthy individuals. Our findings indicate that antibiotic-induced reduction in pathogen burden and changes in the microbiome are independently associated with treatment-induced changes of the inflammatory response of active TB, and the response to antibiotic therapy may be a combined effect of pathogen killing and microbiome driven immunomodulation.
Antibiotic therapy can lead to pathogen clearance, but also to alterations in the gut microbiota and systemic immune responses. Here, the authors analyze data from patients with tuberculosis and healthy subjects to show that pathogen clearance and gut microbiota alterations are independently associated with antibiotic-induced changes of the inflammatory response of active tuberculosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Memorial Sloan Kettering Cancer Center, Immunology Program, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); Weill Cornell Medicine, Clinical and Translational Science Center, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
2 University of Massachusetts Medical School, Department of Microbiology and Physiological Systems, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)
3 Memorial Sloan Kettering Cancer Center, Immunology Program, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); Weill Cornell Medicine, Division of Infectious Diseases, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
4 Memorial Sloan Kettering Cancer Center, Division of Infectious Diseases, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
5 Haitian Study Group for Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti (GRID:grid.51462.34)
6 Weill Cornell Medicine, Center for Global Health, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
7 Haitian Study Group for Kaposi’s Sarcoma and Opportunistic Infections (GHESKIO), Port-au-Prince, Haiti (GRID:grid.5386.8)
8 Memorial Sloan Kettering Cancer Center, Immunology Program, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
9 Weill Cornell Graduate School, Immunology and Microbial Pathogenesis Graduate Program, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
10 Memorial Sloan Kettering Cancer Center, Immunology Program, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952); Weill Cornell Medicine, Division of Infectious Diseases, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Weill Cornell Graduate School, Immunology and Microbial Pathogenesis Graduate Program, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
11 University of Massachusetts Medical School, Department of Microbiology and Physiological Systems, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Center for Microbiome Research, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Medical School, Program in Systems Biology, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)